Oncolytics Biotech Q4 EPS $(0.04) Beats $(0.11) Estimate
Portfolio Pulse from totan@benzinga.com
Oncolytics Biotech (NASDAQ:ONCY) reported Q4 earnings with losses of $(0.04) per share, surpassing the analyst consensus estimate of $(0.11) by 63.64%. This represents a 60% improvement over the previous year's losses of $(0.10) per share.
March 07, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech reported a smaller loss than expected in Q4, with a per-share loss of $(0.04), beating estimates and showing significant improvement over the previous year.
The positive earnings report from Oncolytics Biotech, showing a significant beat on analyst expectations and a notable improvement over the previous year's performance, is likely to instill investor confidence and could lead to a short-term uptick in ONCY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100